Musashino Red Cross Hospital, Tokyo
Ribavirin may act as a mutagen in treatment of chronic hepatitis C
Published in Law and Health Weekly, December 3rd, 2005
Y. Asahina and colleagues, Musashino Red Cross Hospital, undertook the study "to elucidate whether ribavirin acts as a mutagen in the clinical setting and to clarify the relationship between ribavirin-induced mutations and virological response to combined therapy."
"Thirty-four patients with hepatitis C virus (HCV) genotype 1b received ribavirin monotherapy for 4 weeks, followed by a 24-week course of IFN/ribavirin therapy. HCV mutations during a non-treatment observation period and...
Want to see the full article?
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Law and Health Weekly
More Articles from Law and Health Weekly
- Cardinal Health, Inc.
Ivan K. Fong named chief legal officer at pharmaceutical, medical supply company - Center for Information & Study on Clinical Resea
Media coverage of prescription drug safety deters clinical trial participation - Dynavax Technologies Corp.
Nancy L. Buc, former U.S. FDA chief counsel, joins board of directors - Finance
Home health company reports 2.2% decrease in revenue - Florida State University
Florida researcher's device grows quantities of adult stem cells for research - Greatbatch, Inc.
Component maker enters into a tantalum capacitor license agreement with Medtronic - More from this issue of Law and Health Weekly
NewsRx is Social
Follow us on your favorite social network by clicking on a button below:
Top Medical Newsletters
Awards
Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005
Facts & Stats
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.
- Google 2010 PageRank: #2 Among Top Health News and Media Publications
- Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
- Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
- Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry
